Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible by Othman, Tamer, Baird, John H., Wang, Yan, Pak, Stacy, Aldoss, Ibrahim, Cai, Ji-Lian, Danilov, Alexey, Phillips, Tycel J., Agrawal, Vaibhav, Sandhu, Karamjeet S, Mei, Matthew, Koller, Paul B., Palmer, Joycelynne Michelle, Forman, Stephen J., Budde, Lihua E., Aribi, Ahmed

Get full text

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma by Kambhampati, Swetha, Merryman, Reid W., Wang, Yan, Gaulin, Charles, Bezerra, Evandro, Voorhees, Timothy, Seshadri, Madhav R, Falade, Ayo S, Habib, Alma, Ayers, Amy A., Bailey, Megumi, Brown, Annette, Bailey, Neil, Patel, Krish, Andreadis, Charalambos, Kittai, Adam S, Jacobson, Caron A., Palmer, Joycelynne Michelle, Forman, Stephen J., Nastoupil, Loretta, Budde, Lihua E.

Get full text

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy by Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C, Al Malki, Monzr M., Aribi, Ahmed, Sandhu, Karamjeet S., Salhotra, Amandeep, Agrawal, Vaibhav, Pourhassan, Hoda, Koller, Paul B., Ali, Haris, Artz, Andrew, Amanam, Idoroenyi, Karras, Nicole, Pawlowska, Anna, Murphy, Lindsey, Palmer, Joycelynne Michelle, Marcucci, Guido, Stein, Anthony, Pullarkat, Vinod, Nakamura, Ryotaro, Forman, Stephen J.

Get full text

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma by Kambhampati, Swetha, Merryman, Reid W., Wang, Yan, Bezerra, Evandro, Voorhees, Timothy, Falade, Ayo S, Seshadri, Madhav R, Bailey, Megumi, Bailey, Neil, Patel, Krish, Andreadis, Charalambos, Kittai, Adam S, Jacobson, Caron A, Palmer, Joycelynne Michelle, Brown, Annette, Herrera, Alex F., Budde, L. Elizabeth

Get full text

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia by Tinajero, Jose, Ngo, Dat, Zhang, Jianying, Tsai, NI-Chun, Palmer, Joycelynne Michelle, Aribi, Ahmed, Aldoss, Ibrahim, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Pourhassan, Hoda, Sandhu, Karamjeet S., Al Malki, Monzr M., Pullarkat, Vinod, Becker, Pamela S., Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Artz, Andrew, Koller, Paul B., Salhotra, Amandeep

Get full text

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status by Aldoss, Ibrahim, Pham, Anh, Li, Sierra Min, Gendzekhadze, Ketevan, Afkhami, Michelle, Telatar, Milhan, Hong, Hao, Padeganeh, Abbas, Bedell, Victoria, Cao, Thai, Khaled, Samer K, Malki, Monzr M Al, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Palmer, Joycelynne, Aoun, Patricia, Spielberger, Ricardo, Stein, Anthony S, Snyder, David, O'Donnell, Margaret R, Murata-Collins, Joyce, Senitzer, David, Weisenburger, Dennis, Forman, Stephen J, Pullarkat, Vinod, Marcucci, Guido, Pillai, Raju, Nakamura, Ryotaro

Get full text

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma by Chen, Robert, Palmer, Joycelynne M, Martin, Peter, Tsai, Nicole, Kim, Young, Chen, Bihong T, Popplewell, Leslie, Siddiqi, Tanya, Thomas, Sandra H, Mott, Michelle, Sahebi, Firoozeh, Armenian, Saro, Leonard, John, Nademanee, Auayporn, Forman, Stephen J

Get full text

Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status by Nakamura, Ryotaro, Aldoss, Ibrahim, Pham, Anh, Li, Sierra Min, Gendzekhadze, Ketevan, Afkhami, Michelle, Telatar, Milhan, Hong, Hao, Padeganeh, Abbas, Bedell, Victoria, Cao, Thai, Khaled, Samer, Al Malki, Monzr M., Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Palmer, Joycelynne M., Aoun, Patricia, Spielberger, Ricardo, Stein, Anthony S., Snyder, David S., O'Donnell, Margaret R., Murata-Collins, Joyce, Senitzer, David, Weisenburger, Dennis D., Forman, Stephen J., Pullarkat, Vinod, Marcucci, Guido, Pillai, Raju

Get full text

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT by Chen, Robert, Palmer, Joycelynne, Martin, Peter, Armenian, Saro, Tsai, Nichun, Mott, Michelle, Sahebi, Firoozeh, Cai, Ji-Lian, Siddiqi, Tanya, Popplewell, Leslie L., Leonard, John P., Nademanee, Auayporn P., Rosen, Steven T., Kwak, Larry W., Forman, Stephen J.

Get full text

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT by Chen, Robert W, Palmer, Joycelynne, Martin, Peter, Tsai, Nicole, Kim, Young, Mott, Michelle, Sahebi, Firoozeh, Siddiqi, Tanya, Popplewell, Leslie L., Leonard, John P., Shore, Tsiporah B., Forman, Stephen J.

Get full text

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL by Chen, Robert W., Palmer, Joycelynne, Siddiqi, Tanya, Thomas, Sandra H., Kim, Young, Binhong, Chen T, Krishnan, Amrita, Nathwani, Nitya, Cai, Ji-Lian, Mott, Michelle, Matsuoka, Deron, Forman, Stephen J

Get full text